A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia

Mohebbi, Alireza; Shahriyary, Fahimeh; Farrokhi, Vida; Bandar, Bita; Saki, Najmaldin

doi:10.1016/j.leukres.2024.107505

Leukemia Research

2024

DOI: 10.1016/j.leukres.2024.107505

|View full text |Cite

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia

Alireza Mohebbi,

Fahimeh Shahriyary,

Vida Farrokhi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments

Travaglini,

Gurnari,

Ottone

et al. 2024

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review FLT3 mutations are among the most common myeloid drivers identified in adult acute myeloid leukemia (AML). Their identification is crucial for the precise risk assessment because of the strong prognostic significance of the most recurrent type of FLT3 alterations, namely internal tandem duplications (ITDs). Recent advances in the pathogenesis and biology of FLT3-mutated AML have opened an opportunity for development and application of selective inhibition of FLT3 pathway. Recent findings In the last decade, at least three targeted treatments have been approved by regulatory agencies and several others are currently under investigations. Here, we review the latest advance in the role of FLT3 mutations in AML, providing an outline of the available therapeutic strategies, their mechanisms of actions and of resistance, as well as routes for potential improvement. Summary The availability of FLT3 inhibitors has improved outcomes in AML harboring such mutations, currently also reflected in disease stratification and recommendations. Newer inhibitors are under investigations, and combinations with chemotherapy or other targeted treatments are being explored to further improve disease outcomes.

show abstract

Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments

Travaglini,

Gurnari,

Ottone

et al. 2024

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia

Cited by 1 publication

References 90 publications

Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments

Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments

Contact Info

Product

Resources

About